Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally

Lars R Zebis; Thomas D Christensen; Henrik F Thomsen; Vibeke E Hjortdal

doi:10.1080/14017430701798820

Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally

Lars R Zebis, Thomas D Christensen, Henrik F Thomsen, Vibeke E Hjortdal

Abstract

OBJECTIVE: To evaluate amiodarone prophylaxis in diabetics and non-diabetics. Further to clarify whether the risk of developing atrial fibrillation is higher for diabetics than non-diabetic patients, and to evaluate whether the diabetic status has any influence on the length of in-hospital stay.

DESIGN: Subgroup analysis within a randomized, controlled, double-blinded trial.

RESULTS: At 30 days of follow-up atrial fibrillation was equally frequent among diabetics (22%) and non-diabetics (17%) (p =0.41). The length of in-hospital stay for diabetics was prolonged with 25% (9%; 45%). The prophylactic amiodarone was found equally efficient in diabetics and non-diabetics, as the relative risk ratios were 1.2 (0.4-5.4) and 2.0 (0.3-12.5), respectively.

CONCLUSIONS: Diabetics and non-diabetics had the same effect of the amiodarone prophylaxis regime. Atrial fibrillation developed equally among diabetics and non-diabetics, but the length of stay was prolonged for diabetics.

Originalsprog	Engelsk
Bogserie	Scandinavian Cardiovascular Journal. Supplementum
Vol/bind	42
Udgave nummer	3
Sider (fra-til)	173-7
Antal sider	5
ISSN	1401-7431
DOI	https://doi.org/10.1080/14017430701798820
Status	Udgivet - jun. 2008
Udgivet eksternt	Ja

Adgang til dokumentet

10.1080/14017430701798820

Citationsformater

@article{6be63153c14848ea803b702d4f5e1555,

title = "Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally",

abstract = "OBJECTIVE: To evaluate amiodarone prophylaxis in diabetics and non-diabetics. Further to clarify whether the risk of developing atrial fibrillation is higher for diabetics than non-diabetic patients, and to evaluate whether the diabetic status has any influence on the length of in-hospital stay.DESIGN: Subgroup analysis within a randomized, controlled, double-blinded trial.RESULTS: At 30 days of follow-up atrial fibrillation was equally frequent among diabetics (22%) and non-diabetics (17%) (p =0.41). The length of in-hospital stay for diabetics was prolonged with 25% (9%; 45%). The prophylactic amiodarone was found equally efficient in diabetics and non-diabetics, as the relative risk ratios were 1.2 (0.4-5.4) and 2.0 (0.3-12.5), respectively.CONCLUSIONS: Diabetics and non-diabetics had the same effect of the amiodarone prophylaxis regime. Atrial fibrillation developed equally among diabetics and non-diabetics, but the length of stay was prolonged for diabetics.",

keywords = "Aged, Amiodarone/administration & dosage, Anti-Arrhythmia Agents/administration & dosage, Atrial Fibrillation/etiology, Coronary Artery Bypass/adverse effects, Coronary Artery Disease/drug therapy, Diabetes Mellitus/drug therapy, Double-Blind Method, Drug Administration Schedule, Female, Humans, Length of Stay, Male, Middle Aged, Risk Assessment, Time Factors, Treatment Outcome",

author = "Zebis, {Lars R} and Christensen, {Thomas D} and Thomsen, {Henrik F} and Hjortdal, {Vibeke E}",

year = "2008",

month = jun,

doi = "10.1080/14017430701798820",

language = "English",

volume = "42",

pages = "173--7",

journal = "Scandinavian Cardiovascular Journal. Supplementum",

issn = "1401-7431",

publisher = "Taylor & Francis A S",

number = "3",

}

TY - JOUR

T1 - Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally

AU - Zebis, Lars R

AU - Christensen, Thomas D

AU - Thomsen, Henrik F

AU - Hjortdal, Vibeke E

PY - 2008/6

Y1 - 2008/6

N2 - OBJECTIVE: To evaluate amiodarone prophylaxis in diabetics and non-diabetics. Further to clarify whether the risk of developing atrial fibrillation is higher for diabetics than non-diabetic patients, and to evaluate whether the diabetic status has any influence on the length of in-hospital stay.DESIGN: Subgroup analysis within a randomized, controlled, double-blinded trial.RESULTS: At 30 days of follow-up atrial fibrillation was equally frequent among diabetics (22%) and non-diabetics (17%) (p =0.41). The length of in-hospital stay for diabetics was prolonged with 25% (9%; 45%). The prophylactic amiodarone was found equally efficient in diabetics and non-diabetics, as the relative risk ratios were 1.2 (0.4-5.4) and 2.0 (0.3-12.5), respectively.CONCLUSIONS: Diabetics and non-diabetics had the same effect of the amiodarone prophylaxis regime. Atrial fibrillation developed equally among diabetics and non-diabetics, but the length of stay was prolonged for diabetics.

AB - OBJECTIVE: To evaluate amiodarone prophylaxis in diabetics and non-diabetics. Further to clarify whether the risk of developing atrial fibrillation is higher for diabetics than non-diabetic patients, and to evaluate whether the diabetic status has any influence on the length of in-hospital stay.DESIGN: Subgroup analysis within a randomized, controlled, double-blinded trial.RESULTS: At 30 days of follow-up atrial fibrillation was equally frequent among diabetics (22%) and non-diabetics (17%) (p =0.41). The length of in-hospital stay for diabetics was prolonged with 25% (9%; 45%). The prophylactic amiodarone was found equally efficient in diabetics and non-diabetics, as the relative risk ratios were 1.2 (0.4-5.4) and 2.0 (0.3-12.5), respectively.CONCLUSIONS: Diabetics and non-diabetics had the same effect of the amiodarone prophylaxis regime. Atrial fibrillation developed equally among diabetics and non-diabetics, but the length of stay was prolonged for diabetics.

KW - Aged

KW - Amiodarone/administration & dosage

KW - Anti-Arrhythmia Agents/administration & dosage

KW - Atrial Fibrillation/etiology

KW - Coronary Artery Bypass/adverse effects

KW - Coronary Artery Disease/drug therapy

KW - Diabetes Mellitus/drug therapy

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - Length of Stay

KW - Male

KW - Middle Aged

KW - Risk Assessment

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1080/14017430701798820

DO - 10.1080/14017430701798820

M3 - Journal article

C2 - 18569948

SN - 1401-7431

VL - 42

SP - 173

EP - 177

JO - Scandinavian Cardiovascular Journal. Supplementum

JF - Scandinavian Cardiovascular Journal. Supplementum

IS - 3

ER -

Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater